SCHEMBL429677

SCHEMBL429677

Cc1cc(N)cc(Br)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1354865 0.97 ALDH1A1 (0.63) —
SCHEMBL249769 0.85 — —
SCHEMBL6291138 0.82 ALDH1A1 (0.48) —
SCHEMBL33318 0.82 — —
Hydrochloric Acid SCHEMBL2862643 0.78 ALDH1A1 (0.92) —
SCHEMBL2016306 0.78 — —
SCHEMBL21611339 0.78 ALDH1A1 (0.92) —
Bromide SCHEMBL22747715 0.78 ALDH1A1 (0.92) —
SCHEMBL219619 0.78 — —
SCHEMBL178488 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103041855-B Preparation method of catalysts for dichloro-pyridine oxynitride SHANGHAI NOVEL CHEMICAL TECHNOLOGY CO LTD 2014-09-10 — — CN claimed
CN-103041855-A Preparation method of catalysts for dichloro-pyridine oxynitride SHANGHAI NOVEL CHEMICAL TECHNOLOGY CO LTD 2013-04-17 — — CN claimed
US-20260124205-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
EP-4713330-A1 TRICYCLIC COMPOUNDS AND USES THEREOF HUTCHMED Limited (CN) 2026-03-25 — — EP disclosed
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2026-03-05 — — US disclosed
CN-121586713-A Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases 百济神州(苏州)生物科技有限公司 2026-02-27 — — CN disclosed
EP-4665735-A1 KRAS INHIBITORS Erasca, Inc. (US) 2025-12-24 — — EP disclosed
WO-2025245105-A1 KRAS INHIBITORS ERASCA, INC. (US) 2025-11-27 — — WO disclosed
EP-4650002-A1 ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) Ludwig-Maximilians-Universität (DE) 2025-11-19 — — EP disclosed
US-12459925-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NodThera Limited (GB) 2025-11-04 — — US disclosed
US-12398097-B2 WDR5-MYC inhibitors VANDERBILT UNIVERSITY (US) 2025-08-26 — — US disclosed
US-7135600-B2 Selective beta 2-adrenoreceptor agonists; rapid onset of action, long duration; such as 3-(4-{[6-{(-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)hexyl]oxy}butyl)benzenesulfonamide; synthesis GLAXO GROUP LIMITED (GB) 2006-11-14 — — US disclosed
CN-1266126-C Phenylethanolamine derivatives for the treatment of respiratory diseases GLAXO GROUP LTD (GB) 2006-07-26 — — CN disclosed
US-20040180876-A1 Phenethanolamine derivatives for treatment of respiratory diseases GLAXO GROUP LIMITED (GB) 2004-09-16 — — US disclosed
CN-1501911-A Phenethanolamine derivatives for treatment of respiratory diseases — 2004-06-02 — — CN disclosed
EP-1360174-A1 PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-11-12 — — EP disclosed
WO-2002066422-A1 PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES GLAXO GROUP LIMITED (GB) 2002-08-29 — — WO disclosed
US-5270309-A Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders MERCK SHARP & DOHME LIMITED (GB) 1993-12-14 — — US disclosed
EP-0303387-B1 KYNURENIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS MERCK SHARP & DOHME LTD. (GB) 1993-04-21 — — EP disclosed
EP-0303387-A1 Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders MERCK SHARP & DOHME LTD. (GB) 1989-02-15 — — EP disclosed
Send feedback